ATE328590T1 - Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan - Google Patents
Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindanInfo
- Publication number
- ATE328590T1 ATE328590T1 AT97927353T AT97927353T ATE328590T1 AT E328590 T1 ATE328590 T1 AT E328590T1 AT 97927353 T AT97927353 T AT 97927353T AT 97927353 T AT97927353 T AT 97927353T AT E328590 T1 ATE328590 T1 AT E328590T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- aminoindane
- propargyl
- disease
- compositions containing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000014674 injury Diseases 0.000 abstract 4
- 208000027418 Wounds and injury Diseases 0.000 abstract 3
- 230000006378 damage Effects 0.000 abstract 3
- 206010021143 Hypoxia Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002660 Anoxia Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 231100000189 neurotoxic Toxicity 0.000 abstract 1
- 230000002887 neurotoxic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11883696A IL118836A (en) | 1996-07-11 | 1996-07-11 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE328590T1 true ATE328590T1 (de) | 2006-06-15 |
Family
ID=11069065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97927353T ATE328590T1 (de) | 1996-07-11 | 1997-06-20 | Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6277886B1 (enExample) |
| EP (1) | EP0929298B1 (enExample) |
| JP (1) | JP4368421B2 (enExample) |
| CN (1) | CN1149985C (enExample) |
| AT (1) | ATE328590T1 (enExample) |
| AU (1) | AU3188097A (enExample) |
| CA (1) | CA2260037C (enExample) |
| DE (1) | DE69736066T2 (enExample) |
| HU (1) | HU226961B1 (enExample) |
| IL (1) | IL118836A (enExample) |
| NO (1) | NO326052B1 (enExample) |
| WO (1) | WO1998002152A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| AU2002244247B2 (en) | 2001-03-01 | 2007-12-13 | Harbor Biosciences, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
| JP2006506445A (ja) | 2002-08-28 | 2006-02-23 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 治療処置の方法 |
| AU2003282337B2 (en) * | 2002-11-07 | 2009-07-16 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| EP1567152B1 (en) | 2002-11-15 | 2013-08-14 | Teva Pharmaceutical Industries Limited | Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis |
| US8097608B2 (en) * | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
| EP1686973A4 (en) * | 2003-11-25 | 2009-03-25 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES |
| JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
| CA2582231A1 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| HRP20130622T1 (en) * | 2005-02-17 | 2013-08-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2901244A1 (en) | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| US8263655B2 (en) | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
| JP2009521402A (ja) | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| CN103142570A (zh) | 2005-12-09 | 2013-06-12 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 低剂量Ladostigil 用于神经保护的用途 |
| EP1991214B1 (en) | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| RS52183B (sr) * | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| BRPI0718339A2 (pt) * | 2006-12-14 | 2014-02-18 | Teva Pharma | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009032273A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| WO2009089049A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| US20110027354A1 (en) * | 2008-04-01 | 2011-02-03 | Kim Hyoung-Chun | Anti-parkinsonian compounds |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| BRPI0909997A2 (pt) | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| CN102791258B (zh) | 2010-02-03 | 2018-05-08 | 图必制药公司 | 雷沙吉兰的延长释放制剂及其用途 |
| WO2012015946A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| HK1200314A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceuticals Usa, Inc. | R(+)-n-methyl-propargyl-aminoindan |
| HK1200315A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
| US9308182B2 (en) | 2012-08-17 | 2016-04-12 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of rasagiline |
| CN104177610A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
| CN104177611A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
| CN111333517A (zh) * | 2018-12-19 | 2020-06-26 | 上海奥博生物医药技术有限公司 | 一种制备雷沙吉兰的改进方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| EP0738149B1 (en) * | 1994-01-10 | 2006-11-29 | Teva Pharmaceutical Industries, Ltd. | 1-aminoindan derivatives and compositions thereof |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
-
1996
- 1996-07-11 IL IL11883696A patent/IL118836A/xx not_active IP Right Cessation
-
1997
- 1997-06-20 AU AU31880/97A patent/AU3188097A/en not_active Abandoned
- 1997-06-20 EP EP97927353A patent/EP0929298B1/en not_active Expired - Lifetime
- 1997-06-20 HU HU9904525A patent/HU226961B1/hu unknown
- 1997-06-20 JP JP50580698A patent/JP4368421B2/ja not_active Expired - Lifetime
- 1997-06-20 CA CA002260037A patent/CA2260037C/en not_active Expired - Lifetime
- 1997-06-20 DE DE69736066T patent/DE69736066T2/de not_active Expired - Lifetime
- 1997-06-20 AT AT97927353T patent/ATE328590T1/de not_active IP Right Cessation
- 1997-06-20 WO PCT/IL1997/000205 patent/WO1998002152A1/en not_active Ceased
- 1997-06-20 CN CNB971971994A patent/CN1149985C/zh not_active Expired - Lifetime
-
1999
- 1999-01-08 NO NO19990088A patent/NO326052B1/no not_active IP Right Cessation
- 1999-01-11 US US09/228,153 patent/US6277886B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4368421B2 (ja) | 2009-11-18 |
| WO1998002152A1 (en) | 1998-01-22 |
| NO990088L (no) | 1999-03-10 |
| HU226961B1 (en) | 2010-03-29 |
| NO326052B1 (no) | 2008-09-08 |
| JP2000514453A (ja) | 2000-10-31 |
| CN1227486A (zh) | 1999-09-01 |
| IL118836A (en) | 2001-01-11 |
| NO990088D0 (no) | 1999-01-08 |
| EP0929298B1 (en) | 2006-06-07 |
| CN1149985C (zh) | 2004-05-19 |
| HUP9904525A2 (hu) | 2000-11-28 |
| CA2260037A1 (en) | 1998-01-22 |
| AU3188097A (en) | 1998-02-09 |
| CA2260037C (en) | 2007-01-23 |
| DE69736066T2 (de) | 2006-12-28 |
| EP0929298A1 (en) | 1999-07-21 |
| US6277886B1 (en) | 2001-08-21 |
| DE69736066D1 (de) | 2006-07-20 |
| HUP9904525A3 (en) | 2000-12-28 |
| IL118836A0 (en) | 1996-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69736066D1 (de) | Pharmazeutische zusammensetzungen enthaltend s-(-)-n-propargyl-1-aminoindan | |
| HU913447D0 (en) | Medical preparations and their use in treating neurologic disorders | |
| NL300205I1 (nl) | N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van verschillende ziekten, en mesylaat, esylaat en sulfaat daarvan. | |
| GB2254784B (en) | Film-coated solid dosage form of anti-migraine drug | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| MY130145A (en) | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders. | |
| MX9708977A (es) | Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas. | |
| CA2122058A1 (en) | Tgf-beta to improve neural outcome | |
| CA2111836A1 (en) | Spin-trapping pharmaceutical compositions and methods for use thereof | |
| MX9603489A (es) | Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos. | |
| CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
| ATE202709T1 (de) | Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten | |
| DE69835435D1 (de) | Anti-arrhythmische zusammensetzungen und behandlungsverfahren | |
| CA2374997A1 (en) | Il6ril6 chimera for the treatment of neurodegenerative diseases | |
| MXPA01009384A (es) | Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina. | |
| CA2135752A1 (en) | Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease | |
| CA2097878A1 (en) | Therapeutic agent for neutropenia | |
| NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
| CA2154485A1 (en) | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders | |
| RU93004536A (ru) | Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя | |
| IT1264428B1 (it) | Composizioni farmaceutiche per il trattamento della psoriasi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |